Oncology Central

The evolving field of post-transplant therapy in multiple myeloma


Multiple myeloma is characterized by monoclonal protein production, immune dysregulation, renal dysfunction and lytic bone disease. The backbone of therapy for patients eligible for high-dose therapy has been induction therapy followed by consolidation with autologous stem cell transplant. The introduction of immunomodulatory drugs and proteasome inhibitors has led to a dramatic improvement in responses to induction therapy, translating to improved survival following transplant.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.